

FY2025 R&D Tax Incentive Loan Funding

Melbourne, Australia, 30 June 2025: Rhythm Biosciences Ltd ('RHY', the 'Company' or the 'Group') (ASX:RHY), a transformative, predictive cancer diagnostics technology company, advises it has received a tranche of \$1m in non-dilutive funding from Endpoints Capital ("EndPoints") under a funding facility secured against the Company's Research and Development Tax Incentive ("RDTI").

The drawdown funding amount of \$1.0m (\$1.14m total funding approved) is secured by and repayable via the FY25 RDTI Rebate, with repayment due concurrent with receipt of the rebate anticipated later in 2025 and interest being charged at commercial rates consistent with facilities of this nature.

The funding will be used in ongoing operations including the planned commercial launch of the new, multiplex assay version of ColoSTAT®, commercial sales distribution activities for geneType™, further R&D studies into other cancer diagnostics in both proteomics and genomics, developing and securing partnerships and day-to-day working capital requirements.

The Australian Government RDTI program provides eligible companies with a rebate against research and development related expenditure by way of refundable tax offset.

Dr. David Atkins commented: *"Endpoints' non-dilutive funding package is a strong vote of confidence in the strength of our RDTI program. After a thorough due diligence process on our anticipated FY25 RDTI, Endpoints approved the loan—further boosting our balance sheet. This funding support accelerates our momentum as we hit key milestones for ColoSTAT® and expand the geneType™ product line's pipeline and customer base."*

- ENDS -

This announcement was authorised by the Board of Directors of Rhythm Biosciences Limited.

For further information contact us via investors@rhythmbio.com.

About Rhythm Biosciences

Rhythm Biosciences Ltd (ASX: RHY) is an Australian innovative, medical diagnostics company aimed at delivering simple, affordable blood tests for accurate and early detection of cancers. Rhythm is focused on improving patient outcomes through detection at the earliest possible stage, reducing the global burden of cancer and saving lives.

Rhythm Biosciences is committed to working with likeminded global partners to achieve commercialisation and distribution of these simple solutions.

The company was founded in 2017 and is headquartered in Melbourne, Australia. For more information, visit rhythmbio.com and follow the company on LinkedIn and X.

About ColoSTAT®

Colorectal cancer (CRC), also referred to as bowel cancer, is the second leading cause of cancer deaths globally. If diagnosed early, colorectal cancer is curable.

Rhythm Biosciences Ltd
ACN 619 459 335
ASX: RHY

www.rhythmbio.com

Australian Registered Address
Bio21 Molecular Science & Biotechnology Institute
30 Flemington Road
Parkville VIC 3010 Australia

T +61 3 8256 2880
E info@rhythmbio.com

Directors

Otto Buttula
Sue MacLeman
Gavin Fox-Smith
David Atkins

Non-Executive Chairman
Non-Executive Director
Non-Executive Director
CEO & Managing Director

The ColoSTAT® Test-Kit is Rhythm Bioscience's simple blood-based test for the detection of CRC. It measures five specific protein biomarkers that indicate the likelihood of CRC. The test is an alternative for individuals who are unable or unwilling to participate in current screening programs. It is being updated to meet relevant regulatory standards.

The ColoSTAT® Test-Kit is based on research from Australia's CSIRO and is patent protected internationally. It has the potential to play a key role in reducing the mortality rate and healthcare costs associated with colorectal cancer.

About geneType™

geneType™ is a sophisticated genetic risk assessment testing platform that combines clinical, family history and genetic data to provide comprehensive risk assessments for various diseases. The platform leverages polygenic risk scores and clinical risk factors to generate personalized health insights, helping individuals and healthcare providers make more informed medical decisions. The technology allows for risk assessment across multiple conditions including breast cancer, cardiovascular disease, diabetes, colorectal cancer, prostate cancer and melanoma. The tests are delivered through healthcare providers and genetic counsellors, ensuring appropriate clinical oversight and support for patients receiving their results. The platform's multi-disease assessment capabilities and clinical utility position it well to capture growing demand in the preventative healthcare and precision medicine markets. For more information, please visit www.genetype.com.